The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses how the loss of BCMA can occur in patients with multiple myeloma, and further highlights treatment options available when this occurs, including GPRC5D- and FcRH5-targeting agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Novartis, Roche
